Estrogen modulates the differential expression of cardiac myocyte chymase isoforms and diastolic function

  • Hao WangEmail author
  • Xuming Sun
  • Sarfaraz Ahmad
  • Jing Su
  • Carlos Maria Ferrario
  • Leanne Groban


Chymases, a family of serine proteases with chymotryptic activity, play a significant role in cardiac angiotensin II (Ang II) formation from its substrate Ang-(1-12) in both human and rodent models. No studies, to date, have assessed the differences in enzymatic activity among these isoforms in Ang II formation, particularly in the cardiomyocyte (CM). Using PCR and DNA sequencing, we demonstrated that MCP-1, MCP-2, MCP-4, and MCP-5 mRNAs are expressed in the CM of both spontaneously hypertensive rats (SHR) and normotensive Wistar–Kyoto rats (WKY). While rMCP-1 and rMCP-5 gene transcripts were higher than that of other isoforms in both rat strains, WKY CM exhibits higher levels of rMCP-1 and rMCP-5 mRNAs compared to the SHR CM. Ovariectomy (OVX) increased the expression of rMCP-1 and rMCP-5 mRNAs in WKY. In SHR, OVX was associated with a blunted increase in rMCP-1 mRNA compared to OVX normotensive WKY. Chymase activity, measured as Ang II formation from Ang-(1-12), significantly correlated with rMCP-1 and rMCP-5 mRNA expression in both rat strains. Both rMCP-1 and rMCP-5 mRNA expressions were positively correlated with progressive diastolic dysfunction (increasing the ratio of early mitral inflow velocity-to-early mitral annular velocity, E/e′) and expanding chamber dimensions or increasing left ventricular internal diameter end diastole. These data show rMCP-1 and rMCP-5 as the Ang II forming chymase isoforms participating in the loss of normal cardiac function due to OVX in rodents.


Mast cell protease Chymase Cardiomyocyte Hypertension Ovariectomy Angiotensin-(1-12) 



We thank Marina Lin for her technical assistance.


This work was funded by grants from the National Heart Lung and Blood Institute (CMF and LG) P01-HL051952 and the National Institute on Aging (LG) AG033727 of the National Institute of Health.

Compliance of ethical standards

Conflict of interest

Authors declare that there are no competing interests associated with the manuscript.

Research involving human participants and/or animals

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.


  1. 1.
    Ondetti MA (1991) Angiotensin converting enzyme inhibitors. An overview. Hypertension 18:III134–III135CrossRefGoogle Scholar
  2. 2.
    Ondetti MA, Williams NJ, Sabo EF, Pluscec J, Weaver ER, Kocy O (1971) Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry 10:4033–4039CrossRefGoogle Scholar
  3. 3.
    Carretero OA, Oparil S (2000) Essential hypertension. Part I: definition and etiology. Circulation 101:329–335CrossRefGoogle Scholar
  4. 4.
    Pfeffer MA (1995) ACE inhibition in acute myocardial infarction. N Engl J Med 332:118–120CrossRefGoogle Scholar
  5. 5.
    Hood WB Jr (1993) Role of converting enzyme inhibitors in the treatment of heart failure. J Am Coll Cardiol 22(4):154A–157ACrossRefGoogle Scholar
  6. 6.
    Ferrario CM, Mullick AE (2017) Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res 125:57–71CrossRefGoogle Scholar
  7. 7.
    Reyes S, Varagic J, Ahmad S, VonCannon J, Kon ND, Wang H, Groban L, Cheng CP, Dell’Italia LJ, Ferrario CM (2017) Novel cardiac intracrine mechanisms based on Ang-(1-12)/chymase axis require a revision of therapeutic approaches in human heart disease. Curr Hypertens Rep 19:16CrossRefGoogle Scholar
  8. 8.
    Dusing R (2016) Mega clinical trials which have shaped the RAS intervention clinical practice. Ther Adv Cardiovasc Dis 10:133–150CrossRefGoogle Scholar
  9. 9.
    Ferrario CM (2010) Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control. Life Sci 86:289–299CrossRefGoogle Scholar
  10. 10.
    Ferrario CM, Ahmad S, Varagic J, Cheng CP, Groban L, Wang H, Collawn JF, Dell Italia LJ (2016) Intracrine angiotensin II functions originate from noncanonical pathways in the human heart. Am J Physiol Heart Circ Physiol 311:H404–H414CrossRefGoogle Scholar
  11. 11.
    Urata H, Healy B, Stewart RW, Bumpus FM, Husain A (1990) Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 66:883–890CrossRefGoogle Scholar
  12. 12.
    Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A (1990) Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265:22348–22357Google Scholar
  13. 13.
    Dell’Italia LJ, Collawn JF, Ferrario CM (2018) Multifunctional role of chymase in acute and chronic tissue injury and remodeling. Circ Res 122:319–336CrossRefGoogle Scholar
  14. 14.
    Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM (2011) Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. PLoS ONE 6:e28501CrossRefGoogle Scholar
  15. 15.
    Ahmad S, Varagic J, VonCannon JL, Groban L, Collawn JF, Dell’Italia LJ, Ferrario CM (2016) Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme. Biochem Biophys Res Commun 478:559–564CrossRefGoogle Scholar
  16. 16.
    Caughey GH (2013) Chymases. In: Rawlings NDS, Salvesen G (eds) Handbook of proteolytic enzymes, 3rd edn. Academic Press, London, pp 2675–2682CrossRefGoogle Scholar
  17. 17.
    Caughey GH, Beauchamp J, Schlatter D, Raymond WW, Trivedi NN, Banner D, Mauser H, Fingerle J (2008) Guinea pig chymase is leucine-specific: a novel example of functional plasticity in the chymase/granzyme family of serine peptidases. J Biol Chem 283:13943–13951CrossRefGoogle Scholar
  18. 18.
    Takai S, Jin D (2016) Improvement of cardiovascular remodelling by chymase inhibitor. Clin Exp Pharmacol Physiol 43:387–393CrossRefGoogle Scholar
  19. 19.
    Kanefendt F, Thuss U, Becka M, Boxnick S, Berse M, Schultz A, Otto C (2018) Pharmacokinetics, safety, and tolerability of the novel chymase inhibitor BAY 1142524 in healthy male volunteers. Clin Pharmacol Drug Dev. Google Scholar
  20. 20.
    Susic D, Frohlich ED (2011) Hypertensive cardiovascular and renal disease and target organ damage: lessons from animal models. Cardiorenal Med 1:139–146CrossRefGoogle Scholar
  21. 21.
    Caughey GH, Raymond WW, Wolters PJ (2000) Angiotensin II generation by mast cell alpha- and beta-chymases. Biochim Biophys Acta 1480:245–257CrossRefGoogle Scholar
  22. 22.
    Lützelschwab C, Pejler G, Aveskogh M, Hellman L (1997) Secretory granule proteases in rat mast cells. Cloning of 10 different serine proteases and a carboxypeptidase A from various rat mast cell populations. J Exp Med 185:13–29CrossRefGoogle Scholar
  23. 23.
    Ahmad S, Sun X, Lin M, Varagic J, Zapata-Sudo G, Ferrario CM, Groban L, Wang H (2018) Blunting of estrogen modulation of cardiac cellular chymase/RAS activity and function in SHR. J Cell Physiol 233:3330–3342CrossRefGoogle Scholar
  24. 24.
    Ahmad S, Wei CC, Tallaj J, Dell’Italia LJ, Moniwa N, Varagic J, Ferrario CM (2013) Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc Hypertens 7:128–136CrossRefGoogle Scholar
  25. 25.
    Jessup JA, Wang H, MacNamara LM, Presley TD, Kim-Shapiro DB, Zhang L, Chen AF, Groban L (2013) Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats. Menopause 20:860–868CrossRefGoogle Scholar
  26. 26.
    Zhang X, Cheng HJ, Zhou P, Kitzman DW, Ferrario CM, Li WM, Cheng CP (2017) Cellular basis of angiotensin-(1-7)-induced augmentation of left ventricular functional performance in heart failure. Int J Cardiol 236:405–412CrossRefGoogle Scholar
  27. 27.
    Zhou P, Cheng CP, Li T, Ferrario CM, Cheng HJ (2015) Modulation of cardiac L-type Ca2+ current by angiotensin-(1-7): normal versus heart failure. Ther Adv Cardiovasc Dis 9:342–353CrossRefGoogle Scholar
  28. 28.
    Wang H, Sun X, Chou J, Lin M, Ferrario CM, Zapata-Sudo G, Groban L. Inflammatory and mitochondrial gene expression data in GPER-deficient cardiomyocytes from male and female mice. Data Brief 10:465–473Google Scholar
  29. 29.
    Wang H, Jessup JA, Zhao Z, Da Silva J, Lin M, MacNamara LM, Ahmad S, Chappell MC, Ferrario CM, Groban L (2013) Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats. PLoS ONE 8:e76992CrossRefGoogle Scholar
  30. 30.
    Fu L, Wei CC, Powell PC, Bradley WE, Ahmad S, Ferrario CM, Collawn JF, Dell’Italia LJ (2016) Increased fibroblast chymase production mediates procollagen autophagic digestion in volume overload. J Mol Cell Cardiol 92:1–9CrossRefGoogle Scholar
  31. 31.
    Karlson U, Pejler G, Froman G, Hellman L (2002) Rat mast cell protease 4 is a beta-chymase with unusually stringent substrate recognition profile. J Biol Chem 277:18579–18585CrossRefGoogle Scholar
  32. 32.
    Parks RJ, Howlett SE (2013) Sex differences in mechanisms of cardiac excitation–contraction coupling. Pflugers Arch 465:747–763CrossRefGoogle Scholar
  33. 33.
    Ribeiro RF Jr, Pavan BM, Potratz FF, Fiorim J, Simoes MR, Dias FM, Lima FL, Fernandes AA, Vassallo DV, Stefanon I (2012) Myocardial contractile dysfunction induced by ovariectomy requires at1 receptor activation in female rats. Cell Physiol Biochem 30:1–12CrossRefGoogle Scholar
  34. 34.
    Fu Z, Thorpe M, Hellman L (2015) rMCP-2, the major rat mucosal mast cell protease, an analysis of its extended cleavage specificity and its potential role in regulating intestinal permeability by the cleavage of cell adhesion and junction proteins. PLoS ONE 10:e0131720CrossRefGoogle Scholar
  35. 35.
    Levick SP, Melendez GC, Plante E, McLarty JL, Brower GL, Janicki JS (2011) Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res 89:12–19CrossRefGoogle Scholar
  36. 36.
    Ferrario CM, Varagic J, Habibi J, Nagata S, Kato J, Chappell MC, Trask AJ, Kitamura K, Whaley-Connell A, Sowers JR (2009) Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol 296:H1184–H1192CrossRefGoogle Scholar
  37. 37.
    Nagata S, Kato J, Kuwasako K, Asami M, Kitamura K (2012) Plasma and tissue concentrations of proangiotensin-12 in rats treated with inhibitors of the renin-angiotensin system. Hypertens Res 35:234–238CrossRefGoogle Scholar
  38. 38.
    Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K (2006) Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 350:1026–1031CrossRefGoogle Scholar
  39. 39.
    Jessup JA, Trask AJ, Chappell MC, Nagata S, Kato J, Kitamura K, Ferrario CM (2008) Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. Am J Physiol Heart Circ Physiol 294:H2614–H2618CrossRefGoogle Scholar
  40. 40.
    Gardner JD, Murray DB, Voloshenyuk TG, Brower GL, Bradley JM, Janicki JS (2010) Estrogen attenuates chronic volume overload induced structural and functional remodeling in male rat hearts. Am J Physiol Heart Circ Physiol 298:H497–H504CrossRefGoogle Scholar
  41. 41.
    Baka T, Hodosy J, Krajcirovicova K, Repova K, Aziriova S, Domonkos E, Borbelyova V, Slavkovsky P, Zorad S, Celec P, Paulis L, Simko F (2018) 17β-Estradiol treatment reversed left ventricular dysfunction in castrated male rats: an echocardiographic study. Can J Physiol Pharmacol 96:850–854CrossRefGoogle Scholar
  42. 42.
    Soliman M (2015) Protective effects of estradiol on myocardial contractile function following hemorrhagic shock and resuscitation in rats. Chin Med J (Engl) 128:2360–2364CrossRefGoogle Scholar
  43. 43.
    Devanathan S, Whitehead T, Schweitzer GG, Fettig N, Kovacs A, Korach KS, Finck BN, Shoghi KI (2014) An animal model with a cardiomyocyte-specific deletion of estrogen receptor alpha: functional, metabolic, and differential network analysis. PLoS ONE 9:e101900CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of AnesthesiologyWake Forest School of MedicineWinston-SalemUSA
  2. 2.Department of Internal Medicine-Molecular MedicineWake Forest School of MedicineWinston-SalemUSA
  3. 3.Department of SurgeryWake Forest School of MedicineWinston-SalemUSA
  4. 4.Division of Public Health Sciences, Department of Biostatistical SciencesWake Forest School of MedicineWinston-SalemUSA
  5. 5.Department of Physiology and PharmacologyWake Forest School of MedicineWinston-SalemUSA
  6. 6.Division of Public Health Sciences, Department of Social Sciences and Health PolicyWake Forest University School of MedicineWinston-SalemUSA

Personalised recommendations